Etiometry
Boston, US · Delaware corporation · 1 known investors
Find your way into Etiometry
236 people in our graph share verified history with the Etiometry team — schools, employers, funds. One of them is your warm intro.
Etiometry develops a clinical decision support platform that uses continuous streams of physiologic data to quantify clinical risks for patients in hospital critical care and intensive care units. The company applies AI-based predictive analytics to support clinicians managing critically ill patients.
Also known as Etiometry, Inc.
Founders & leadership
Investors · 1
Reported raises · per SEC filings
Form D private placements$15.6M disclosed across 3 rounds · 2017–2022
▶$10MraisedApr 2024 · 7 investors · Other Health CareRule 506(b)
- David ShepherdDirector
- Evan ButlerExecutive Officer, Director
- Gregory S. MartinDirector
- Guy Lyndon FishDirector
- Shane CookeExecutive Officer, Director
- Dimitar BaronovExecutive Officer
- Brad RosenblumExecutive Officer
- Offering amount
- $14M
- Amount sold
- $10M
- First sale
- Jan 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.1MraisedMar 2021 · 24 investors · Other Health CareRule 506(b)
- Bradley RosenblumExecutive Officer
- Evan ButlerExecutive Officer, Director
- Shane CookeExecutive Officer, Director
- Guy Lyndon FishDirector
- Gregory S. MartinDirector
- David ShepherdDirector
- Dimitar BaronovExecutive Officer
- Offering amount
- $9M
- Amount sold
- $5.1M
- First sale
- Sep 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$500KraisedOct 2017 · 3 investors · Other Health CareRule 506(b)
- Evan ButlerExecutive Officer, Director
- Eric MeyersDirector
- Nelson StacksDirector
- Dimitar BaronovExecutive Officer, Director
- Peter RockExecutive Officer, Director
- Jesse LockExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $500K
- First sale
- Sep 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Etiometry, based in Boston, Massachusetts, develops a clinical intelligence software platform for high-acuity hospital care teams, including intensive care units and pediatric/neonatal critical care. The platform aggregates and visualizes patient data drawn from bedside monitoring systems, peripheral medical devices, electronic health records and other clinical data sources, and layers risk analytics intended to surface physiologic pathways that can lead to poor outcomes. It positions itself as an AI assistant for hemodynamic and respiratory management in the ICU, supporting both escalation and de-escalation of care decisions.
Beyond data display and risk analytics, the product supports automation of hospital-defined clinical pathways so that workflows reflect an individual institution's guidelines, and provides long-term clinical data storage and reporting used for quality-improvement programs and research. The company states its platform has 11 FDA clearances and has enabled more than 150 studies. Etiometry notes that reported outcome associations are observational and that the platform is intended to aid decision-making rather than to improve outcomes independently.
Business model
Etiometry licenses its software platform to hospitals, which deploy it across critical care units alongside existing monitoring, device and EHR infrastructure; the site markets institutional partnerships and demo requests rather than individual user sales.
Traction
The company reports 11 FDA clearances and more than 150 studies enabled by its platform, and cites published and presented results including reductions in ICU length of stay of up to 36%, ICU readmissions of up to 41%, ventilation time of up to 30%, and 29% shorter vasoactive infusion duration, along with a survey finding 88% of nurses said the platform made their jobs easier.
Latest developments
In April 2026 Etiometry announced a retrospective analysis presented at the Pediatric Academic Societies 2026 Meeting evaluating changes in blood gas measurement frequency following platform use, and in June 2026 announced research published in Pediatric Critical Care Medicine on impaired oxygen delivery analytics. Recent media coverage included a Medscape interview featuring co-founder and CTO Dimitar Baronov and a Neonatology Today feature on data use in neonatal care.
▸Full profile — market position, technology, go-to-market, geography, risks & controversies
Market position
Etiometry describes its offering as the only FDA-cleared clinical intelligence platform of its kind and cites adoption by academic medical centers recognized by U.S. News & World Report and top-ranked children's hospitals listed in Newsweek's World's Best Specialized Hospitals.
Technology
The platform ingests continuous streams of physiologic data from monitors, peripheral devices and EHRs, applies risk analytics — including impaired oxygen delivery analytics — and AI-based decision support for hemodynamic and respiratory management, and adds a clinical pathway automation layer plus long-term data storage and reporting for quality improvement and research use.
Go-to-market
Direct institutional sales supported by demo requests on the company website, peer-reviewed publications and conference presentations (for example at the Pediatric Academic Societies meeting), clinician testimonials from partner hospitals, and trade-press features in outlets such as Medscape and Neonatology Today.
Hospital critical care and intensive care programs, including pediatric ICUs, cardiac ICUs and neonatal units, at academic medical centers and children's hospitals; end users include intensivists, cardiologists and ICU nursing staff.
Geography
Headquartered in Boston, Massachusetts, with named clinical relationships at U.S. institutions including Boston Children's Hospital and Washington University School of Medicine.
Risks & controversies
The company states that reported clinical results are observational and that the platform is intended to aid clinician decision-making rather than to improve outcomes independently.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Competitors · 3
by search overlap
Companies competing with Etiometry for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 6 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2015 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2013 | $300.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $498.2K |
| Department of DefenseDefense Health Program | Phase I | 2011 | $149.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2011 | $99.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Timeline · 2
launches, deals, and filingsThe company announced new research published in Pediatric Critical Care Medicine on impaired oxygen delivery analytics.
Etiometry announced a retrospective analysis presented at the PAS 2026 Meeting evaluating changes in blood gas measurement frequency following use of its platform.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities · 1
corporate structureIn the news
▸Research sources · 1
primary sources listed
- Etiometryetiometry.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Etiometry do?
- Etiometry sells an FDA-cleared clinical intelligence platform that turns continuous physiologic data into ICU decision support.
- Who founded Etiometry?
- Etiometry was founded by Evan Butler, Dimitar Baronov.
- Who are Etiometry's investors?
- Etiometry's investors include Escalate Capital Partners.
- How much funding has Etiometry raised?
- Etiometry has disclosed $15.6M raised across 3 rounds.
- Where is Etiometry headquartered?
- Etiometry is headquartered in Boston, US.